vs

Side-by-side financial comparison of Chaince Digital Holdings Inc. (CD) and Coeptis Therapeutics Holdings, Inc. (COEP). Click either name above to swap in a different company.

Coeptis Therapeutics Holdings, Inc. is the larger business by last-quarter revenue ($862.0K vs $466.6K, roughly 1.8× Chaince Digital Holdings Inc.). Coeptis Therapeutics Holdings, Inc. runs the higher net margin — -146.5% vs -640.5%, a 494.1% gap on every dollar of revenue.

Coeptis Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cancer immunotherapies, including cell therapy and antibody-based treatment candidates, to address unmet medical needs for patients with hard-to-treat malignancies. It primarily operates in the U.S., advancing its product pipeline across multiple oncology segments.

CD vs COEP — Head-to-Head

Bigger by revenue
COEP
COEP
1.8× larger
COEP
$862.0K
$466.6K
CD
Higher net margin
COEP
COEP
494.1% more per $
COEP
-146.5%
-640.5%
CD

Income Statement — Q2 FY2025 vs Q4 FY2025

Metric
CD
CD
COEP
COEP
Revenue
$466.6K
$862.0K
Net Profit
$-3.0M
$-1.3M
Gross Margin
94.8%
Operating Margin
-665.1%
-230.6%
Net Margin
-640.5%
-146.5%
Revenue YoY
Net Profit YoY
55.1%
EPS (diluted)
$-0.05
$0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CD
CD
COEP
COEP
Q4 25
$862.0K
Q3 25
$237.4K
Q2 25
$466.6K
$200.7K
Q1 25
$62.9K
Q4 24
$0
Q3 24
$0
Q2 24
$0
Q1 24
$0
Net Profit
CD
CD
COEP
COEP
Q4 25
$-1.3M
Q3 25
$-2.9M
Q2 25
$-3.0M
$-4.3M
Q1 25
$-3.4M
Q4 24
$-2.8M
Q3 24
$-1.8M
Q2 24
$-3.0M
Q1 24
$-3.0M
Gross Margin
CD
CD
COEP
COEP
Q4 25
94.8%
Q3 25
81.0%
Q2 25
77.5%
Q1 25
28.2%
Q4 24
Q3 24
Q2 24
Q1 24
Operating Margin
CD
CD
COEP
COEP
Q4 25
-230.6%
Q3 25
-1043.2%
Q2 25
-665.1%
-2252.9%
Q1 25
-6452.6%
Q4 24
Q3 24
Q2 24
Q1 24
Net Margin
CD
CD
COEP
COEP
Q4 25
-146.5%
Q3 25
-1220.8%
Q2 25
-640.5%
-2159.9%
Q1 25
-5440.9%
Q4 24
Q3 24
Q2 24
Q1 24
EPS (diluted)
CD
CD
COEP
COEP
Q4 25
$0.05
Q3 25
$-0.58
Q2 25
$-0.05
$-1.17
Q1 25
$-1.11
Q4 24
$-5.35
Q3 24
$-0.05
Q2 24
$-0.08
Q1 24
$-0.08

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CD
CD
COEP
COEP
Cash + ST InvestmentsLiquidity on hand
$27.2M
$676.6K
Total DebtLower is stronger
$150.0K
Stockholders' EquityBook value
$29.4M
$13.6M
Total Assets
$36.6M
$16.2M
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CD
CD
COEP
COEP
Q4 25
$676.6K
Q3 25
$421.7K
Q2 25
$27.2M
$990.6K
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Total Debt
CD
CD
COEP
COEP
Q4 25
$150.0K
Q3 25
$150.0K
Q2 25
$150.0K
Q1 25
Q4 24
$150.0K
Q3 24
$1.7M
Q2 24
$1.7M
Q1 24
$2.3M
Stockholders' Equity
CD
CD
COEP
COEP
Q4 25
$13.6M
Q3 25
$10.4M
Q2 25
$29.4M
$6.1M
Q1 25
$6.5M
Q4 24
$3.4M
Q3 24
$4.8M
Q2 24
$-442.6K
Q1 24
$-1.1M
Total Assets
CD
CD
COEP
COEP
Q4 25
$16.2M
Q3 25
$14.2M
Q2 25
$36.6M
$12.2M
Q1 25
$13.5M
Q4 24
$8.9M
Q3 24
$9.0M
Q2 24
$4.2M
Q1 24
$3.9M
Debt / Equity
CD
CD
COEP
COEP
Q4 25
0.01×
Q3 25
0.01×
Q2 25
0.02×
Q1 25
Q4 24
0.04×
Q3 24
0.35×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CD
CD
COEP
COEP
Operating Cash FlowLast quarter
$-1.3M
$-8.6M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CD
CD
COEP
COEP
Q4 25
$-8.6M
Q3 25
$-2.2M
Q2 25
$-1.3M
$-2.4M
Q1 25
$-2.4M
Q4 24
$-6.6M
Q3 24
$-1.9M
Q2 24
$-1.4M
Q1 24
$-1.9M

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons